ASRS 2023: The Starlight study
August 6th 2023Michael Singer, MD, spoke with our team about the Starlight Study, an optogenetic study looking at patients who had Stargardt's disease at the 2023 ASRS annual meeting. At the meeting, Nanoscope Therapeutics Inc presented key results from its STARLIGHT Phase 2 clinical trial.
Read More
ASRS Live: 27-Gauge vs 25-gauge vitrectomy for symptomatic vitreous opacities
July 31st 2023Our team spoke with Shawn Kavoussi, MD, at the 2023 ASRS meeting in Seattle, Washington about his research on using infrared video for vitreous opacities and comparing postoperative reduction in vitreous opacity scores using infrared video with the Heidelberg spectralis unit.
Read More
ASRS Live: Presentations and topics at ASRS that are key for retina specialists
July 30th 2023Our team spoke with Michael Ip, MD, to get his perspective on the 2023 ASRS meeting in Seattle, Washington and why he thinks these are the most valuable topics to understand and review for retina specialists.
Read More
ASRS Live: Results of GATHER 1 and GATHER 2 clinical trials with Carl Danzig, MD
July 29th 2023Carl Danzig, MD, spoke with our team to share the exciting results of the GATHER 1 and GATHER 2 clinical trials for avacincaptad pegol for the treatment of geographic atrophy at the 2023 ASRS annual meeting.
Read More
ASRS Live: Aaron Lee, MD, shares updates on deep learning research
July 29th 2023At the 2023 ASRS meeting in Seattle, Washington, Aaron Lee, MD, spoke with our team about his research and how changes are making new training possible. He shared how research and new techniques are expanding the options for deep learning in ophthalmology.
Read More
Alkeus announces funding and the appointment of Joshua Boger to executive chairman
June 7th 2023The $150 Million Series B funding will allow for the registration and launch of gilderuretinol, the first and only medicine in clinical development to address the underlying mechanism of Stargardt disease.
Read More
Annexon announces topline results from ARCHER Phase 2 trial of ANX007 for geographic atrophy
May 29th 2023Data supports ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection, but reduction in rate of geographic atrophy lesion growth did not reach statistical significance.
Read More
ASCRS 2023: Safety and effectiveness of the Dexamethasone Hydrogel-Based insert
May 12th 2023Patrick Spencer, DO, discussed the safety and effectiveness comparison of hydrogel-based intracanalicular dexamethasone insert placement in the lower versus the upper punctum at the 2023 ASCRS annual meeting in San Diego.
Read More